(FILES) In this undated handout image obtained July 15, 2020, courtesy of National Institute of Allergy and Infectious Diseases(NIH/NIAID), shows a colorized scanning electron micrograph of an apoptotic cell (blue/green) heavily infected with SARS-COV-2 virus particles (yellow), isolated from a patient sample, captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. - US pharmaceutical company Eli Lilly's combination of two synthetic antibodies against Covid-19 reduced hospitalizations and deaths by 70 percent in high-risk patients with recent positive tests, the company said on January 26, 2021. "Bamlanivimab and etesevimab together have the potential to be an important treatment that significantly reduces hospitalizations and death in high-risk COVID-19 patients," Lilly's chief scientific officer Daniel Skovronsky said. (Photo by Handout / National Institute of Allergy and Infectious Diseases / AFP) / RESTRICTED TO EDITORIAL USE - MANDATORY CREDIT "AFP PHOTO /NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES/HANDOUT " - NO MARKETING - NO ADVERTISING CAMPAIGNS - DISTRIBUTED AS A SERVICE TO CLIENTS